A genome-wide association study revealed an association between variants of the inosine triphosphatase (ITPA) gene and ribavirin (RBV)-induced anaemia. The aim of this study was to replicate this finding in an independent Japanese cohort and to define a method to allow pretreatment prediction of anaemia in combination with other factors.
Methods
Genotype 1b chronic hepatitis C patients (n=132) treated with pegylated interferon (PEG-IFN)-α and RBV for 48 weeks were genotyped for ITPA rs1127354 and examined for anaemia and treatment outcome.
Results
Variants of the ITPA gene protected against severe anaemia throughout the 48-week treatment period and were associated with lower incidence of anaemia-related RBV dose reduction. A combination of the ITPA genotype with baseline haemoglobin (Hb) and creatinine clearance (CLcr) levels predicted severe anaemia with high accuracy (90% sensitivity and 62% specificity). Among a subset of patients with the IL28B genotype of TT at rs8099917, patients with variants of the ITPA gene were associated with a higher rate of receiving >80% of the expected RBV dose, a higher rate of sustained virological response (SVR), and a lower rate of relapse.
Conclusions
The variants of the ITPA gene, which could protect against haemolytic anaemia and RBV dose reduction, were associated with a high rate of SVR by standard PEG-IFN and RBV therapy in a subset of Japanese patients with the favourable TT genotype at rs8099917 of IL28B. A combination of ITPA genetic polymorphisms with baseline Hb and CLcr levels further improves the predictive accuracy of severe anaemia.
References
1.
FriedM.W., ShiffmanM.L., ReddyK.R.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med2002; 347: 975–982.
2.
MannsM.P., McHutchisonJ.G., GordonS.C.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet2001; 358: 958–965.
3.
McHutchisonJ.G., MannsM., PatelK.Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology2002; 123: 1061–1069.
4.
FellayJ., ThompsonA.J., GeD.ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature2010; 464: 405–408.
MaedaT., SumiS., UetaA.Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency in the Japanese population. Mol Genet Metab2005; 85: 271–279.
7.
ShipkovaM., LorenzK., OellerichM., WielandE., von AhsenN.Measurement of erythrocyte inosine triphosphate pyrophosphohydrolase (ITPA) activity by HPLC and correlation of ITPA genotype-phenotype in a Caucasian population. Clin Chem2006; 52: 240–247.
8.
AtanasovaS., ShipkovaM., SvinarovD.Analysis of ITPA phenotype-genotype correlation in the Bulgarian population revealed a novel gene variant in exon 6. Ther Drug Monit2007; 29: 6–10.
9.
ThompsonA.J., FellayJ., PatelK.Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology2010; 139: 1181–1189.
10.
OchiH., MaekawaT., AbeH.Inosine triphosphate pyrophosphatase polymorphism affects ribavirin-induced anemia and outcomes of therapy – a genome-wide study of Japanese hepatitis C virus patients. Gastroenterology2010; 139: 1190–1197.
11.
GeD., FellayJ., ThompsonA.J.Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature2009; 461: 399–401.
12.
TanakaY., NishidaN., SugiyamaM.Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet2009; 41: 1105–1109.
13.
SuppiahV., MoldovanM., AhlenstielG.IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet2009; 41: 1100–1104.
14.
RauchA., KutalikZ., DescombesP.Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology2010; 138: 1338–1345.
15.
NishidaN., TanabeT., TakasuM., SuyamaA., TokunagaK.Further development of multiplex single nucleotide polymorphism typing method, the DigiTag2 assay. Anal Biochem2007; 364: 78–85.
16.
EnomotoN., SakumaI., AsahinaY.Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med1996; 334: 77–82.
17.
KurosakiM., EnomotoN., MurakamiT.Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy. Hepatology1997; 25: 750–753.
18.
AkutaN., SuzukiF., SezakiH.Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology2005; 48: 372–380.
19.
CockcroftD.W., GaultM.H.Prediction of creatinine clearance from serum creatinine. Nephron1976; 16: 31–41.
20.
BedossaP., PoynardT.An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology1996; 24: 289–293.
21.
TanakaY., NishidaN., SugiyamaM., TokunagaK., MizokamiM.λ-Interferons and the single nucleotide polymorphisms: a milestone to tailor-made therapy for chronic hepatitis C. Hepatol Res2010; 40: 449–460.
22.
BronowickiJ.P., OuzanD., AsselahT.Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology2006; 131: 1040–1048.
23.
McHutchisonJ.G., LawitzE.J., ShiffmanM.L.Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med2009; 361: 580–593.
24.
McHutchisonJ.G., EversonG.T., GordonS.C.Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med2009; 360: 1827–1838.
25.
KwoP.Y., LawitzE.J., McConeJ.Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre Phase 2 trial. Lancet2010; 376: 705–716.
26.
HiramatsuN., OzeT., TsudaN.Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy?Hepatol Res2006; 35: 185–189.
27.
IwasakiY., IkedaH., ArakiY.Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology2006; 43: 54–63.
